Premium
Serum albumin varies by tumor stage in cutaneous malignant melanoma (LB347)
Author(s) -
Datta Mridul,
Schwartz Gary
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.lb347
Subject(s) - medicine , albumin , melanoma , serum albumin , cancer , calcium , gastroenterology , stage (stratigraphy) , biomarker , cancer research , chemistry , biochemistry , biology , paleontology
High albumin adjusted serum calcium has been reported in several cancers but has not been studied in malignant melanoma. We examined the relationship between serum albumin, total and corrected calcium in malignant melanoma in a cross‐sectional study. Two thousand three hundred six patients with cutaneous melanoma were identified between Jan. 2000 and Dec. 2010 and 644 met our inclusion criteria. At the time of diagnosis, total serum calcium was non‐significantly lower in stage 4 (9.34 mg/dL) vs. stages 1‐3 (9.48‐9.51 mg/dL). Serum albumin was significantly lower in stage 4 (3.92 g/dL; p蠄0.05) than stages 0‐3 (4.09‐4.15 g/dL). Higher albumin corrected serum calcium was observed with increasing melanoma stage (9.45‐9.61 mg/dL). Men but not women showed a significant decrease in serum albumin in stage 4 when compared with stages 1‐3 (p = 0.02). Patients >75 years had significantly lower serum albumin (3.98±0.33 vs 4.16±0.35 g/dL; p<0.001), but higher adjusted calcium (9.64±0.49 vs 9.53±0.43 mg/dL; p=0.03) compared to patients 蠄 75 years. Serum albumin may serve as a biomarker to evaluate disease progression in cutaneous malignant melanoma patients. Grant Funding Source : Dr. Datta is supported by the Comprehensive Cancer Center of Wake Forest University Cancer Control Traineeship ‐ NCI/NIH Grant# #R25CA122061.